Health
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
H. Lundbeck A/S (Lundbeck) today announced the full results from the SUNRISE trial, a randomized, placebo-controlled trial designed to evaluate the efficacy and safety of eptinezumab versus placebo in a predominantly Asian population with chronic migraine. The study was presented at the 11th Congress of the European Academy of Neurology taking place in Helsinki 21-24 June.1
About this update from Healtheuniverse Inc
[{"type":"list","items":[{"val":[{"type":"text","content":"The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMDs) compared with placebo1","length":269,"tagName":"p"}]},{"val":[{"type":"text","content":"Patients receiving eptinezumab were four times more likely to achieve a reduction of ≥75% in MMDs within the first 4 weeks, compared to placebo1","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"The SUNRISE trial met all key secondary efficacy endpoints with improvements seen as early as day 1 and sustained through week 121 ","length":142,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":560,"olType":false},{"type":"text","content":"VALBY, Denmark, June 21, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced the full results from the SUNRISE trial, a randomized, placebo-controlled trial designed to evaluate the efficacy and safety of eptinezumab versus placebo in a predominantly Asian population with chronic migraine. The study was presented at the 11th Congress of the European Academy of Neurology taking place in Helsinki 21-24 June.1","length":422,"tagName":"p"},{"type":"text","content":""Various treatments are recommended for patients with migraine in Asia, however utilization and adherence to migraine-specific treatment is relatively low. Access to effective treatments remains a significant unmet medical need for migraine prevention in Asia" said Johan Luthman, EVP and Head of R&D at Lundbeck. "The data from SUNRISE is consistent with previous results across diverse populations and will be pivotal for our efforts to expand access to eptinezumab for patients in Asia suffering with severe migraine."","length":545,"tagName":"p"},{"type":"text","content":"The double-blind, pivotal, SUNRISE trial (n=983) met all key primary and secondary endpoints, with eptinezumab demonstrating greater reductions in migraine frequency, the proportion of migraine attacks with severe pain, and disease burden, compared to placebo.1","length":266,"tagName":"p"},{"type":"text","content":""The SUNRISE trial marks a significant step forward in the mission to make migraine-specific preventive treatmen...